The BRI Blog
For recent medical community news and insights, engage with our recent posts below.
Sally Pipes: “Democrats Can’t End Private-Sector Drug Innovation Fast Enough”
December 16, 2025 by bmew
Expanding Medicare’s price controls into the private market would make the business of drug discovery all but impossible in the U.S.—and mark the end of America’s reign as the world’s leading source of life-saving medicines.
Sally Pipes: “Chaos At The FDA Benefits America’s Rivals—At The Expense Of America’s Patients”
December 15, 2025 by bmew
A chaotic FDA is incompatible with a thriving, competitive market for medical discovery. Any effort to reform the agency must prioritize removing barriers and avoiding delays that keep safe, effective medicines from reaching patients.
Sally Pipes: “Despite Dems’ Protests, Affordable Health Plans Are About to Multiply”
December 12, 2025 by bmew
A mix of catastrophic coverage, HSAs, and direct primary care can help Americans get better care at a lower cost than a conventional Obamacare plan. Here’s how.
Sally Pipes Addresses ALEC Summit on the Hidden Costs of Pharmaceutical Price Controls
December 11, 2025 by bmew
Drug price controls don’t simply make medicine more affordable. Rather, the heavy hand of government stifles medical innovation and weakens one’s biopharmaceutical sector—as countless other nations have proven.
Sally Pipes: “Trade Policy Is The Right Way To Fight Foreign Freeloading”
December 8, 2025 by bmew
A recent trade deal between the U.S. and the U.K. proves how the government can ensure other countries pick up a greater share of the global drug-development without imposing state-mandated price controls.
Sally Pipes: “‘Soak the Rich’ Won’t Rescue Calif. Healthcare”
December 3, 2025 by bmew